Until 2022, Russia was one of the largest suppliers of oil and gas to EU countries. With the start of a full-scale invasion ...

Q3 2025 Management View Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X ...

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studi ...

A tech build-out reshapes Umatilla and its neighbours with jobs, money and megaprojects—along with rising costs and new risks ...

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first 'off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the ...

Prelude Therapeutics Incorporated continues to explore the SMARCA2 anticancer approach. Click here to read why PRLD stock is ...

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate ...

A new genomic method has enabled multiple people with rare conditions to receive diagnoses that were previously unattainable ...

UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and ...

Caribou Biosciences, Inc. recently reported very exciting early data, with more in the allogeneic CAR T-cell pipeline. Read ...

"Retail is our largest RAM segment and has been growing at 18–20%. MSME and Agri are also seeing strong growth, 14% and 17%, respectively," he told FE.

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...